.
In The Outsiders, William Thorndike studied the profiles of eight unconventional CEOs whose independent thinking and disciplined capital allocation created extraordinary value for their stakeholders. In this post, we explore how the teachings in this book can be applied to the medical device industry to provide long-term value to shareholders and support sustainable adoption of innovative healthcare solutions.
Capital allocation is your core job
Every dollar raised is an investment decision. Decide if it belongs in clinical trials, regulatory work, reimbursement strategy, or partnerships based on expected return.
Calculate returns on every decision
Run ROI models for trials, distributor agreements, hiring, and partnerships. Use conservative assumptions. Everything in MedTech takes longer and costs more than you think.
Raise money with discipline
Each round of funding must increase your odds of commercial success more than the dilution it costs. Don’t raise money just to hit vanity milestones.
Keep operations lean
Early on, outsource regulatory, quality, and marketing rather than over-building HQ. Keep fixed costs low so cash goes to activities that move the product forward.
Cut what doesn’t create value
If a product line, new clinical indication research, or trial isn’t delivering strong returns or adoption potential, stop investing. Even if it’s scientifically exciting.
Double down on what matters
Focus resources on the one milestone that unlocks adoption and reimbursement. Whether that’s a pivotal trial, a single claim, or a first reimbursement approval.
Think unconventionally about markets
Don’t follow the standard “CE mark → Europe → FDA” path by default. For example, if adoption and purchasing cycles are faster in the Middle East, start there, generate evidence and revenue, and then re-enter Europe stronger. If you already have a large list of potential clients in LATAM, drive adoption in the region before using a more conventional market. The best path is not always the obvious one.
Design for decentralization
Use distributors, local KOLs, and CROs to reach markets quickly. Give partners autonomy but hold them accountable to clear value-based KPIs. Align compensation with long-term value creation.
Reshape strategically
Spin off, out-license, or divest non-core IP or divisions if it sharpens focus and extends runway. Staying focused beats trying to do everything.
Ignore vanity metrics
A CE mark, FDA approval, pilot site, or press coverage means little without adoption and reimbursement. Measure success by sustainable patient use and payer coverage.
Act boldly when timing is right
Be frugal daily, but move decisively on asymmetric opportunities. Exclusive distributor deals, early reimbursement pathways, or acquiring complementary IP.
Surround yourself with expert advisors
Build a circle of regulatory, reimbursement, clinical, and capital allocation experts. Their input prevents expensive mistakes and gives credibility with investors.
Empower teams, enforce accountability
Let internal staff and external partners make decisions, but tie accountability to measurable outcomes like trial milestones, reimbursement progress, or revenue targets.
Lead with humility, learning and openness
MedTech is too complex for one person to master. Stay curious, listen, and keep learning from clinicians, payers, regulators, and your team.
Focus on long-term value creation
Always ask: Does this increase the company’s survival odds and long-term adoption? Align decisions to sustainable patient and shareholder value, not short-term optics.